Why the study?
Does a multimodal surveillance strategy integrating LVGLS, LASr, and hs-TnI predict early anthracycline-induced cardiotoxicity in female breast cancer patients?
Population
50 female breast cancer patients treated with anthracycline-based chemotherapy, mean age 49.3 ± 8.5 years.
Design
Cohort
Follow-up
1 month after chemotherapy
Authors
Loading...
A multimodal approach combining LVGLS, LASr, and hs-TnI effectively predicts early anthracycline-induced cardiotoxicity in breast cancer patients, with hs-TnI demonstrating the highest discriminative ability.
Does a multimodal surveillance strategy integrating LVGLS, LASr, and hs-TnI predict early anthracycline-induced cardiotoxicity in female breast cancer patients?
A multimodal approach combining LVGLS, LASr, and hs-TnI effectively predicts early anthracycline-induced cardiotoxicity in breast cancer patients, with hs-TnI demonstrating the highest discriminative ability.
Kaya et al. (2026) studied this question.